Bethan Blackledge
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
Papers in
-
- COVID-19 Clinical Research Studies 12
- SARS-CoV-2 and COVID-19 Research 2
- Genetics 7
- Genetic Associations and Epidemiology 7
- Journals
- The Lancet (7 papers)Nature (4 papers)Nature Communications (2 papers)EClinicalMedicine (1 paper)JAMA (1 paper)
- Partner nations
- United KingdomSwedenVietnam
In The Last Decade
Bethan Blackledge
21 papers receiving 3k citations
Bethan Blackledge's Hit Papers
Peers
Comparison fields: 5 of 102
- Infectious Diseases 1.9k
- Genetics 531
- Applied Microbiology and Biotechnology 35
- Neurology 157
- Internal Medicine 30
Countries citing papers authored by Bethan Blackledge
This map shows the geographic impact of Bethan Blackledge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bethan Blackledge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bethan Blackledge more than expected).
Fields of papers citing papers by Bethan Blackledge
This network shows the impact of papers produced by Bethan Blackledge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bethan Blackledge. The network helps show where Bethan Blackledge may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19 Hit paper breakdown → | 2022 | 252 |
| 6 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 7 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 8 | 2021 | 213 | |
| 9 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 10 | Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial Hit paper breakdown → | 2025 | 94 |
| 11 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 12 | 2023 | 60 | |
| 13 | 2023 | 32 | |
| 14 | 2021 | 26 | |
| 15 | 2023 | 25 | |
| 16 | 2024 | 24 | |
| 17 | 2024 | 8 | |
| 18 | 2024 | 6 | |
| 19 | 2025 | 5 | |
| 20 | 2025 | 4 |
About Bethan Blackledge
Bethan Blackledge is a scholar working on Infectious Diseases, Genetics, Neurology, Pulmonary and Respiratory Medicine and Surgery, having authored 22 papers that have together received 3.2k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (12 papers), Genetic Associations and Epidemiology (7 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Long-Term Effects of COVID-19 (2 papers), Kawasaki Disease and Coronary Complications (1 paper), Parkinson's Disease Mechanisms and Treatments (1 paper) and Respiratory Support and Mechanisms (1 paper). The work is most often cited by research in Infectious Diseases (1.9k citations), Genetics (531 citations), Applied Microbiology and Biotechnology (35 citations), Neurology (157 citations) and Internal Medicine (30 citations). Bethan Blackledge has collaborated with scholars based in United Kingdom, Sweden and Vietnam. Their work appears in journals such as The Lancet, Nature, Nature Communications, EClinicalMedicine and JAMA.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.